Synmosa Biopharma Intangible Assets

Synmosa Biopharma's intangible assets stands at $630M as of June 2026. That compares with $410M in the prior-year period — up 53.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Synmosa Biopharma reported $630M in intangible assets versus $410M a year earlier — a 53.3% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $410M in the prior-year period — up 53.3% year over year. Sustained growth in intangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Synmosa Biopharma's intangible assets evolved across reporting periods, while the comparison chart places 4114.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.